← All organizations
Highest phase reached
Phase 3
First clinical trial
Sep 28, 2010First marketed drug
Jan 25, 2022First NDA
Jan 25, 2022Last known activity
Dec 1, 2024
Timeline
2000s
- Jun 1, 2008
Immunocore Ltd— Founded
2020s
- Jan 25, 2022
tebentafusp— Marketing Organization
- Jan 25, 2022
tebentafusp— NDA Organization
- Jan 25, 2022
tebentafusp— NDA Secondary Org
Drugs by trial phase (20 distinct, 18 trials)
Phase 3 (5 own, 0 via acquisition)
Phase 2 (13 own, 0 via acquisition)
Phase 1 (2 own, 0 via acquisition)
Indications
Studied for
Marketed drugs (1)
Recent trials (21)
- NCT04960891Lead sponsorN/A—
- NCT06627244CollaboratorPhase 2Dec 1, 2024
- NCT07156136Lead sponsorPhase 1Nov 7, 2024
- NCT06246149CollaboratorPhase 3Oct 31, 2024
- NCT06840119Lead sponsorPhase 1/Phase 2Jan 10, 2024
- NCT06112314Lead sponsorPhase 3Dec 1, 2023
- NCT06070012CollaboratorPhase 2Nov 30, 2023
- NCT05549297Lead sponsorPhase 2/Phase 3Nov 30, 2022
- NCT05315258CollaboratorPhase 2Jul 25, 2022
- NCT05867056Lead sponsorPhase 1Aug 12, 2020
- NCT04262466Study directorPhase 1/Phase 2Feb 29, 2020
- NCT04262466Lead sponsorPhase 1/Phase 2Feb 29, 2020
- NCT03973333Lead sponsorPhase 1/Phase 2May 17, 2019
- NCT03515551Lead sponsorPhase 1/Phase 2May 1, 2018
- NCT03070392Lead sponsorPhase 2Jun 1, 2017
Details
- Founded
- Abingdon, GB Jun 1, 2008
- First NDA
- Jan 25, 2022
- Last known activity
- Dec 1, 2024
Designations held
- Orphan drug
- Breakthrough therapy